The combination not only killed the leukemia cells, but also significantly reduced their infiltration into the bone marrow. Acute myeloid leukemia (AML) is an aggressive form of blood cancer in which ...
Cullinan Therapeutics’ T-cell engager, CLN-049, has been proven tolerable and safe in an early-stage study in relapsed or refractory acute myeloid leukaemia (r/r AML) and myelodysplastic syndrome (MDS ...
A multi-institutional team developed a chimeric antigen receptor (CAR) T cell-based strategy for specifically targeting AML cells in patients who relapsed following other treatments. The team ...
Combining proteasome inhibitors with autophagy inhibitors disrupts acute myeloid leukemia (AML) cells' proteostasis, enhancing treatment efficacy and inducing programmed cell death. The novel therapy ...
CLN-049 monotherapy demonstrates promising efficacy, including multiple complete responses and encouraging response durability, in a heavily pretreated all-comer population of patients with R/R AML 31 ...
A research team at Lund University in Sweden has discovered a mechanism that helps acute myeloid leukemia cells to evade the body's immune system. By developing an antibody that blocks the mechanism, ...
Hosted on MSN
What To Know About Acute Myelogenous Leukemia (AML)
Acute myelogenous leukemia (AML), also known as acute myeloid leukemia, is a type of cancer that starts in your bone marrow (the soft, spongy tissue inside the bones that makes blood cells). AML is ...
A comprehensive map of aberrant hematopoiesis in people with acute myeloid leukemia defines specific cell states and potential therapeutic targets. The team used their reference map for normal ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results